# Merck Sharp & Dohme LLC: Phase 3 study in Pulmonary Disease, Chronic Obstructive (2136 participants)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3) |
| NCT ID | NCT07874815 |
| Phase | Phase 3 |
| Status | not yet recruiting |
| Conditions | Pulmonary Disease, Chronic Obstructive |
| Intervention types | drug, other |
| Target enrollment | 2136 |
| Posted | 2026-10-15 |
| Planned start | 2026-10-23 |
| Event | Newly registered study |
| Event date | 2026-10-15 |

## Why this score
- Industry sponsor (buys outsourced services).
- Phase 3: multi-site, larger budget.
- 2136 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07874815). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.